Persistent Asset Partners Ltd Purchases Shares of 101,755 GoodRx Holdings, Inc. (NASDAQ:GDRX)

Key Points

• Persistent Asset Partners Ltd has acquired a new stake in GoodRx Holdings, Inc., purchasing 101,755 shares for approximately $449,000.
• Major shareholder Equity Vii L.P. Spectrum sold 10,677 shares at an average price of $4.80, totaling around $51,250, while insiders collectively own 4.17% of the stock.
• GoodRx's shares have faced recent downgrades from multiple analysts, with Goldman Sachs reducing their price objective from $6.00 to $5.00 and assigning a "neutral" rating.

Persistent Asset Partners Ltd acquired a new position in GoodRx Holdings, Inc. (NASDAQ:GDRX - Free Report) during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 101,755 shares of the company's stock, valued at approximately $449,000.

Several other institutional investors have also recently made changes to their positions in the business. Citizens Financial Group Inc. RI bought a new stake in GoodRx during the 1st quarter worth approximately $44,000. Deerfield Management Company L.P. Series C bought a new position in shares of GoodRx in the fourth quarter worth approximately $56,000. Headlands Technologies LLC raised its position in shares of GoodRx by 213.2% during the first quarter. Headlands Technologies LLC now owns 14,830 shares of the company's stock valued at $65,000 after buying an additional 10,095 shares during the last quarter. Total Wealth Planning & Management Inc. purchased a new position in shares of GoodRx in the fourth quarter worth $68,000. Finally, Oxford Asset Management LLP purchased a new position in shares of GoodRx in the fourth quarter worth $75,000. Institutional investors own 63.77% of the company's stock.

Insider Activity at GoodRx

In related news, major shareholder Equity Vii L.P. Spectrum sold 10,677 shares of the company's stock in a transaction dated Thursday, July 3rd. The shares were sold at an average price of $4.80, for a total value of $51,249.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 4.53% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on GDRX shares. The Goldman Sachs Group lowered their target price on shares of GoodRx from $6.00 to $5.00 and set a "neutral" rating on the stock in a report on Friday, May 9th. Deutsche Bank Aktiengesellschaft reissued a "hold" rating and issued a $6.00 target price on shares of GoodRx in a report on Monday, August 11th. Raymond James Financial cut shares of GoodRx from a "strong-buy" rating to an "outperform" rating in a research report on Friday, August 8th. UBS Group decreased their price target on shares of GoodRx from $6.00 to $5.25 and set a "neutral" rating on the stock in a research note on Tuesday, May 13th. Finally, Wells Fargo & Company decreased their price target on shares of GoodRx from $8.00 to $7.00 and set an "overweight" rating on the stock in a research note on Tuesday, April 29th. Six analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $6.18.

GoodRx Trading Up 5.4%

GDRX stock traded up $0.19 during mid-day trading on Friday, reaching $3.73. 1,636,754 shares of the stock traded hands, compared to its average volume of 1,655,840. The business has a 50-day moving average price of $4.56 and a two-hundred day moving average price of $4.51. The company has a debt-to-equity ratio of 0.75, a quick ratio of 4.21 and a current ratio of 4.21. The stock has a market capitalization of $1.30 billion, a PE ratio of 37.30, a PEG ratio of 1.49 and a beta of 1.24. GoodRx Holdings, Inc. has a one year low of $3.31 and a one year high of $8.80.

GoodRx (NASDAQ:GDRX - Get Free Report) last posted its quarterly earnings results on Wednesday, August 6th. The company reported $0.09 EPS for the quarter, missing analysts' consensus estimates of $0.10 by ($0.01). The company had revenue of $203.07 million during the quarter, compared to the consensus estimate of $205.72 million. GoodRx had a return on equity of 8.86% and a net margin of 4.33%. The company's revenue for the quarter was up 1.2% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.08 earnings per share. Equities research analysts expect that GoodRx Holdings, Inc. will post 0.13 EPS for the current year.

GoodRx Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.